EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy

Shurong Liu, Ye Tian, Sujun Jiang, Zihua Wang iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shurong Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 3…. Hauptthemen laut MEDLINE: Doxorubicin, Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Joint Funds for the Innovation of Science and Technology Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-targeting peptide–drug conjugates (PDCs) have become a focus of research in recent years. However, due to the instability of peptides and their short in vivo effective half-life, they have limited clinical application. Herein, we propose a new DOX PDC based on a homodimer HER-2-targeting peptide and acid-sensitive hydrazone bond, which could enhance the anti-tumor effect of DOX and reduce systemic toxicities. The PDC could accurately deliver DOX into HER2-positive SKBR-3 cells, with it showing 2.9 times higher cellular uptake than free DOX and enhanced cytotoxicity with respect to IC50 of 140 nM (vs. 410 nM for free DOX). In vitro assays showed that the PDC had high cellular internalization efficiency and cytotoxicity. In vivo anti-tumor experiments indicated that the PDC could significantly inhibit the growth of HER2-positive breast cancer xenografts in mice and reduce the side effects of DOX. In summary, we constructed a novel PDC molecule targeting HER2-positive tumors, which may overcome some deficiencies of DOX in breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinBreast NeoplasmsHumansMiceAnimalsFemalePeptidesDrug Delivery SystemsCell Line, Tumor

Stichwörter der Autor:innen

HER-2breast cancerdoxorubicinpeptide–drug conjugatetargeted delivery

Substanzen

DoxorubicinPeptides

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, China.

ORCID-Profile: Zihua Wang

Förderung

  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China
  • Joint Funds for the Innovation of Science and Technology Fujian Province
  • Fujian Medical University Foundation for the Introduction of Talents

Zitieren

APA

Liu, S., Tian, Y., Jiang, S., & Wang, Z. (2023). A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054590

Vancouver

Liu S, Tian Y, Jiang S, Wang Z. A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054590

BibTeX
@article{Liu2023,
  author = {Liu, Shurong and Tian, Ye and Jiang, Sujun and Wang, Zihua},
  title = {A Novel Homodimer Peptide–Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054590}
}
Kostenlos starten →